Viking Therapeutics (VKTX) EBIT (2014 - 2026)

Viking Therapeutics has reported EBIT for 13 years, with the latest figure at -$132.6 million in Q2 2026.

• Quarterly EBIT fell 77.81% year-over-year to -$132.6 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$560.0 million (down 163.12% YoY) and the FY2025 annual result came in at -$393.3 million, down 160.63% from the prior year.
• EBIT advanced to -$132.6 million in Q2 2026 per VKTX's latest filing, from -$164.1 million in the prior quarter.
• Over five years, EBIT peaked at -$16.2 million in Q3 2022 and troughed at -$164.7 million in Q4 2025.
• A 5-year average of -$56.2 million and a median of -$34.1 million in 2024 frame the typical range for EBIT.
• The sharpest annual moves came in 2022 and 2025: EBIT dropped 13.45% in 2022, then tumbled 256.28% in 2025.
• Over 5 years, EBIT stood at -$20.3 million in 2022, then tumbled by 44.38% to -$29.3 million in 2023, then plunged by 57.89% to -$46.2 million in 2024, then sank by 256.28% to -$164.7 million in 2025, then gained by 19.51% to -$132.6 million in 2026.
• According to Business Quant data, EBIT over the past three periods registered -$132.6 million, -$164.1 million, and -$164.7 million for Q2 2026, Q1 2026, and Q4 2025 respectively.